Salvage Therapy in Autoimmune Hepatitis
C
Craig Lammert, MD
Primary Investigator
Enrolling By Invitation
18-100 years
All
Phase
N/A
2 Locations
Brief description of study
The purpose of the study is assess treatment outcomes in people who are taking rituximab as treatment for autoimmune hepatitis (AIH). The treatment itself is not part of the study.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Autoimmune Hepatitis
-
Age: Between 18 Years - 100 Years
-
Gender: All
Inclusion Criteria
Initiation of rituximab as treatment for AIH
Updated on
01 Aug 2024.
Study ID: 1903230072
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
